Multiple Myeloma Clinical Trials in Philadelphia, Pennsylvania

11 studies are recruiting for multiple myeloma in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania

   Locations

   52 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06297226 on ClinicalTrials.gov

2. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

3. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

   The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   50 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05201781 on ClinicalTrials.gov

4. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

   Locations

   144 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07258511 on ClinicalTrials.gov

5. A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refr…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   71 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07266441 on ClinicalTrials.gov

6. AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

   This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Philadelphia, Pennsylvania

   Locations

   43 in total

   Run by

   AstraZeneca

   See if you can join NCT06106945 on ClinicalTrials.gov

7. A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

   A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   26 in total

   Run by

   K36 Therapeutics, Inc.

   See if you can join NCT05651932 on ClinicalTrials.gov

8. Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

   A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Penn Medicine - Abramson Cancer Center Perelman, Philadelphia, Pennsylvania

   Locations

   39 in total

   Run by

   CellCentric Ltd.

   See if you can join NCT04068597 on ClinicalTrials.gov

9. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

   This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Abramson Cancer Center University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

   Locations

   212 in total

   Run by

   European Myeloma Network B.V.

   See if you can join NCT05243797 on ClinicalTrials.gov

10. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania

    Locations

    104 in total

    Run by

    Sumitomo Pharma America, Inc.

    See if you can join NCT04988555 on ClinicalTrials.gov

11. Mozobil for Autologous Hematopoietic Stem Cell Transplantation

    This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

    Run by

    Thomas Jefferson University

    See if you can join NCT07188090 on ClinicalTrials.gov